Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

The gastrointestinal (GI) tract is a major target in GVHD. Conditioning-induced damage and mucosal barrier disruption are important factors in GVHD, however therapies targeting these processes have not been identified. Glucagon-like-peptide 2 (GLP-2) is an enterocyte-specific growth factor produced...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.26-28
Hauptverfasser:	Harle, David W, Macedo Gonzales, Rodney J, Rozenberg, Felix D, Matschiner, Alexandra, Bansal, Rajat, Lagana, Stephen M, Ma, Huihui, Pinker, Elisha, Belay, Kirubel S, Wang, Ximi K, Thomas, Tiffany, Mapara, Markus Y, Uhlemann, Anne-Catrin, Zhang, Yi, Reshef, Ran
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!